![]() cibaria CMU (oraCMU ®, OraPharm, Inc., Seoul, Korea) in a vehicle of distilled water (Daihan Pharma Co., Seoul, Korea). In addition, genotoxicity assessments including bacterial reverse mutations, chromosome aberrations, and micronuclei formation were also conducted. cibaria CMU, by investigating the potential of the strain to cause toxicity to rats after acute or 14 days or 13 weeks of daily exposure. ![]() The purpose of the studies performed for the current evaluation is to add to the current database of safety information on W. cibaria strain have not been reported yet. However, animal toxicity or genotoxicity studies on W. The safety of this strain was confirmed by negative reactions. In addition, the genomic sequence of this strain did not contain any virulence gene, β-hemolysis, mucin degradation, platelet aggregation, and toxic metabolites including d-lactic acid, bile salt deconjugation, ammonia production, β-glucuronidase activity, indole production, nitroreductase activity, phenylalanine degradation, and gelatin liquefaction. cibaria CMU strain, both chromosomal and plasmid, was free of ARGs and revealed no ARGs transferability. cibaria CMU has been examined by phenotypic and genotypic analyses designed to assess the potential for antibiotic resistance, antibiotic resistance gene (ARGs) transferability, virulence, hemolysis, mucin degradation, toxic metabolite production, and platelet aggregation. It is therefore necessary and essential to conduct a safety assessment for this new strain intended as dietary or food supplements for humans. This may be because no application has been submitted with this specific goal. cibaria is on the KFDA Food Ingredient List and is part of the International Dairy Federation List, but is not yet listed as a food ingredient for use in the United States or the European Union. Available commercialized products provide a daily intake of W. The results showed no adverse effects of the strain at the level administrated. cibaria CMU group (0.8 × 10 8 colony forming units (CFU)/day) was compared with a placebo control group in healthy adults to compare the effects on halitosis and periodontal health and examine tolerability. mutans and Streptococcus sobrinus) and periodontopathogens ( Fusobacterium nucleatum and Porphyromonas gingivalis) and inhibition of hydrogen sulfide and methyl mercaptan production by F. cibaria CMU exhibits several properties for maintenance of oral health, including inhibition of biofilm formation by Streptococcus mutans, antibacterial activity against cariogens ( S. cibaria is registered as a safe raw material by the Korea Food and Drug Administration (KFDA) and is found in several commercialized oral care probiotics in Korea. cibaria based on whole genome sequence analysis and phylogenetic homology. cibaria CMU (Chonnam Medical University) has been isolated from saliva samples of children who had little supragingival plaque and no oral diseases including dental caries. Weissella cibaria is described as a short, rod-shaped, Gram-positive, non-spore-forming, nonmotile, heterofermentative, and catalase-negative lactic acid bacterium. The Weissella genus includes a number of heterofermentative Leuconostoc-like lactic acid bacteria that are generally isolated from fermented foods. cibaria strain to cause genetic toxicity and subchronic toxicity in rats according to the Organization for Economic Cooperation and Development guidelines. This study is the first study examining the potential of a W. cibaria CMU to be a safe strain to consume. In conclusion, the toxicological studies performed demonstrated W. cibaria CMU was non-mutagenic in the bacterial reverse mutation test and non-clastogenic or aneugenic in vitro and in vivo. cibaria CMU is > 5000 mg/kg body weight (bw)/day (1.8 × 10 9 CFU/kg bw/day) and the 14-day or 13-week no observed adverse effect level (NOAEL) is 5000 mg/kg bw/day (1.8 × 10 9 CFU/kg bw/day), the highest dose administered. The results of the studies in rats showed that the acute lethal dose of W. cibaria CMU was performed using an acute oral safety study in rats, a 14-day oral range finding study, a subsequent 13-week oral toxicity study in rats and a genetic toxicity battery (in vitro bacterial reverse mutation, in vitro chromosome aberration in Chinese Hamster Ovary cells and in vivo micronucleus study in mice). However, there is a lack of studies assessing its safety in vivo. cibaria CMU (Chonnam Medical University) is expected to be safe based on results of in silico and in vitro analyses. Previous investigations have shown that W. Weissella cibaria belongs to the Lactobacillaceae family and has been isolated from traditional fermented foods and saliva of children with good oral health.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |